Targeted Oncology is a pragmatic tool for all physicians and scientists committed to oncology and cancer research.
Recently, a better understanding of the genetics and biology of cancer have provided important clues to the pathology of the disease and to new therapeutic strategies. Innovative treatments, including small molecule inhibitors and biologicals targeting oncogenic pathways and immune checkpoints have emerged and are currently revolutionizing the way we treat cancer patients. Despite these breakthroughs, significant work remains in understanding these new compounds and identifying markers of treatment success.
Targeted Oncology focuses on Original Research Articles on both pre-clinical and clinical aspects of molecularly targeted agents, and on comprehensive narrative Review Articles discussing clinically established as well as emerging agents and pathways. The journal also publishes Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement, and Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.
Articles published in Targeted Oncology may be accompanied by plain language summaries, to assist patients, caregivers and others in understanding important medical advances.
All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.
The Société française d'angiogenèse is affiliated to the journal.
The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review
Original Research Article
To view the rest of this content please follow the download PDF link above.